UK market is tricky for a few reasons. Very centralized decision-making for healthcare funding, and the timelines are too long for a startup to survive. Plus us Brits are definitely more hesitant of medication approaches in general, although that is changing.

Both my parents, my sister and my brother-in-law work in the NHS - so lots of interesting family conversations about this!

> What was the reason for going after the US market instead of the UK market?

Might have something to do with exorbitant amount of money in the US healthcare.

Bigger spend is definitely important. Drug approval, decentralized decision making, consumer norms all also important.